Analysts' ratings for Bicycle Therapeutics (NASDAQ:BCYC) over the last quarter vary from bullish to bearish, as provided by 11 analysts.

The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.

Insights from analysts' 12-month price targets are revealed, presenting an average target of $41.82, a high estimate of $55.00, and a low estimate of $28.00. Observing a downward trend, the current average is 2.74% lower than the prior average price target of $43.00.

Diving into Analyst Ratings: An In-Depth Exploration

The standing of Bicycle Therapeutics among financial experts is...